Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Seeking Alpha,
Follow Summary Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C.
Follow Summary Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C.
Summit now has quality-of-life data for its ridinilazole to treat Clostridium difficile infections showing benefits over SOC…
NEW YORK (Reuters Health) - Ridinilazole, a novel, targeted-spectrum antimicrobial, was found to be non-inferior to vancomycin…
Our weekly wrap-up of antimicrobial stewardship